Huntington National Bank Decreases Holdings in HCA Healthcare, Inc. (NYSE:HCA)

Huntington National Bank decreased its stake in HCA Healthcare, Inc. (NYSE:HCA) by 5.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,607 shares of the company’s stock after selling 344 shares during the period. Huntington National Bank’s holdings in HCA Healthcare were worth $2,279,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of HCA. MFA Wealth Advisors LLC purchased a new stake in HCA Healthcare during the second quarter valued at about $27,000. Unique Wealth Strategies LLC purchased a new position in HCA Healthcare in the 2nd quarter valued at approximately $28,000. Bangor Savings Bank grew its position in shares of HCA Healthcare by 112.5% in the second quarter. Bangor Savings Bank now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 45 shares in the last quarter. GPS Wealth Strategies Group LLC lifted its holdings in HCA Healthcare by 284.0% during the 2nd quarter. GPS Wealth Strategies Group LLC now owns 96 shares of the company’s stock worth $31,000 after purchasing an additional 71 shares in the last quarter. Finally, Capital Performance Advisors LLP purchased a new stake in shares of HCA Healthcare in the third quarter worth about $41,000. Hedge funds and other institutional investors own 62.73% of the company’s stock.

Insider Buying and Selling at HCA Healthcare

In other news, EVP Michael S. Cuffe sold 8,358 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total value of $3,221,340.36. Following the completion of the transaction, the executive vice president now owns 29,678 shares of the company’s stock, valued at approximately $11,438,494.76. This represents a 21.97 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Erol R. Akdamar sold 2,900 shares of the company’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the sale, the insider now directly owns 6,843 shares in the company, valued at approximately $2,415,579. The trade was a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,155 shares of company stock valued at $5,608,990. 1.60% of the stock is currently owned by company insiders.

HCA Healthcare Stock Performance

HCA Healthcare stock opened at $342.96 on Friday. The firm has a 50-day moving average of $386.00 and a 200-day moving average of $357.03. The firm has a market cap of $86.87 billion, a P/E ratio of 15.40, a P/E/G ratio of 1.34 and a beta of 1.68. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 48.71. HCA Healthcare, Inc. has a 1-year low of $238.82 and a 1-year high of $417.14.

HCA Healthcare Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Friday, December 13th will be paid a $0.66 dividend. This represents a $2.64 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date is Friday, December 13th. HCA Healthcare’s payout ratio is 11.85%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Royal Bank of Canada increased their target price on shares of HCA Healthcare from $378.00 to $405.00 and gave the stock an “outperform” rating in a research note on Friday, August 23rd. Truist Financial upped their target price on HCA Healthcare from $390.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. StockNews.com lowered HCA Healthcare from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. KeyCorp cut their price target on shares of HCA Healthcare from $475.00 to $420.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Finally, UBS Group lifted their price objective on shares of HCA Healthcare from $405.00 to $438.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $385.00.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.